24 results about "Retinoblastoma" patented technology

Presented herein are systems and methods of detecting retinoblastoma using images of eyes. The systems and methods include identifying a first image of at least one first eye of a first subject prior to administration of treatment for retinoblastoma, the at least one eye having a structure of interest corresponding to an abnormality, applying the first image to a machine learning (ML) model established using a training dataset including examples, each of the examples identifying a respective second image of at least one second eye of a second subject and a respective second classification identifying one of presence or absence of retinoblastoma in the at least second eye, determining from applying the ML model, a first classification identifying one of presence or absence of retinoblastoma in the at least one first eye, and storing using one or more data structures, an association between the first subject and the classification.

The present disclosure relates, inter alia, to the combination therapy of an oncolytic adenovirus for the treatment of retinoblastoma, Ewing's sarcoma or neuroblastoma with a topoisomerase I inhibitor or a prodrug thereof, such as topotecan or SN-38, or a prodrug of a topoisomerase inhibitor, such as irinotecan.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

An epigenetic silencer factor (ESF) for use in the treatment of cancer, or a polynucleotide encoding the same, wherein the ESF comprises a transcription factor DNA-binding domain functionally linked to at least one epigenetic effector domain, the transcription factor is an oncogenic transcription factor or a cancer-related transcription factor, and the cancer is selected from the group consisting of glioma, glioblastoma, medulloblastoma, astrocytoma, neuroblastoma, epithelioma, meningioma, retinoblastoma, rhabdomyosarcoma, lung cancer, prostate cancer, breast cancer, liver cancer, pancreatic cancer (e.g., human pancreatic ductal adenocarcinoma), bladder cancer, oropharyngeal cancer, kidney cancer, colon cancer (e.g., colon adenocarcinoma), colorectal cancer (CRC), or metastases of any of the foregoing.

The present invention discloses the use of quetiapine fumarate in the preparation of a drug for treating retinoblastoma. The present invention is the first to discover a new role of quetiapine fumarate in the treatment of retinoblastoma (Rb). Quetiapine fumarate can significantly inhibit the growth of Rb, promote the apoptosis of tumor cells, and effectively treat Rb. The present invention utilizes an Rb organoid model obtained by in vitro induced differentiation of pluripotent stem cells to discover a new role of quetiapine fumarate in the treatment of Rb, providing a new approach to the treatment of Rb. The present invention aims to provide a new drug for the treatment of Rb, improve the effectiveness of tumor treatment, expand the application range of quetiapine fumarate, and provide a reference for clinical medication.

The invention relates to a novel medical application of cinobufagin, and the cinobufagin is used as an N-myc protein inhibition / degradation agent and can be used for anti-tumor treatment of neuroblastoma and retinoblastoma.

The invention discloses an application of a flavonoid natural product Peruvianoside I in preparation of an anti-retinoblastoma drug, belongs to the field of medicinal chemistry, and has the following structure: the compound can selectively inhibit LSD1 enzyme activity and can be used as the anti-retinoblastoma drug. Experiments find that the anti-tumor action mechanism is related to inhibition of retinoblastoma cell migration. As a selective histone lysine specific demethylase LSD1 inhibitor, the compound has the potential of developing the retinoblastoma resisting medicine.

Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.

The application belongs to the technical field of biological medicine, and particularly relates to application of hydroxyurea in preparation of a drug for preventing or treating retinoblastoma, which can achieve the effect of effectively treating RB by specifically targeting ecDNA in retinoblastoma tumor cells, and has high effectiveness and high specificity. The hydroxyurea provided by the application can inhibit the expression of SUZ12 in retinoblastoma cell lines WERI-RB1 or Y79 cells, reduce the modification level of H3K27 trimethylation, and can inhibit the proliferation and tumorigenicity of retinoblastoma cell lines WERI-RB1 or Y79 cells.

This application relates to the technical field of drug applications. This application discloses the use of honokiol in the preparation of a drug for treating retinoblastoma. It is discovered for the first time that honokiol has a new effect in treating retinoblastoma, can effectively inhibit the proliferation of retinoblastoma cells, and is of great significance for the development of new drugs for treating retinoblastoma. Experiments have proven that honokiol can inhibit the proliferation of RB cells by promoting apoptosis of RB cells and inducing cell cycle arrest. This application also discovers for the first time that honokiol has a significant therapeutic effect on multi-drug resistant RB cells, providing a new idea for solving the clinical problem of RB chemotherapy resistance. Experiments have proven that honokiol still maintains good sensitivity to RB drug-resistant cells, and its killing effect on RB / CBP drug-resistant cells is similar to that of RB non-drug-resistant cells.

Heterocyclic compounds, their stereoisomers and their pharmaceutically acceptable salts are useful in the treatment of many types of cancers, such as cancers of the breast, prostate, pancreatic, gastric, lung, colon, rectum, esophagus cancer, duodenum, tongue, pharynx, liver, kidney, bile duct, uterine body, cervix, ovaries, urinary bladder, and skin. Other cancers to be treated include brain tumor, neurinoma, clear cell carcinoma, non-small cell lung cancer, small cell lung cancer, hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer, bone tumor, vascular fibroma, glioblastoma, Neuroblastoma, sarcoma, neuroendocrine tumors, retinoblastoma, penile cancer, pediatric solid cancer, renal cell carcinoma, lymphoma, myeloma, leukemia, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, cutaneous T-cell lymphoma (CTCL), multiple myeloma (MM), myeloproliferative neoplasms (MPN), Myelodysplastic syndrome (MDS), polycythemia vera (PV), essential thrombocythemia, essential thrombocytosis (ET), and myelofibrosis (MF), and also including their metastases.

The invention discloses an in-situ detection system for detecting EZH2 mRNA as well as a preparation method and application of the in-situ detection system. The in-situ detection system comprises a molecular probe compound and a signal amplification compound; the molecular probe compound is constructed from a dCas9-mSA fusion protein and sgRNA of a specific target EZH2 mRNA (messenger Ribonucleic Acid). The signal amplification compound is a metal organic framework nano material encapsulated with fluorescent molecules, and biotin is modified on the metal organic framework nano material; according to the molecular probe compound, Avidin in a dCas9-mSA fusion protein is specifically combined with biotin on the signal amplification compound, so that in-situ labeling and signal amplification of EZH2 mRNA (messenger Ribonucleic Acid) are realized. The in-situ detection system for detecting EZH2 mRNA provided by the invention solves the contradiction that the specificity and the sensitivity are difficult to obtain at the same time in the traditional technology, has the advantages of high sensitivity, strong specificity, good fluorescence quenching resistance, mild operation conditions and the like, can realize in-situ visual detection of tissue slice level EZH2 mRNA, and has a wide application prospect. The kit is especially suitable for auxiliary diagnosis and prognosis evaluation of retinoblastoma.

The invention discloses a novel recombinant protein RB1-PDL1 and application thereof, and belongs to the technical field of biological medicine. The invention has the advantages that: proper hydrophilic modification design is performed on the existing non-functional regions of the retinoblastoma related protein and PD-L1 protein by means of synthetic biology, the anti-tumor activity function of the protein is reserved, the water solubility of the protein is improved, and the defect of poor water solubility of the traditional anti-tumor drug is effectively overcome. The target protein with the effect of killing breast cancer cells and lung cancer cells is obtained on a large scale by means of synthetic biology, and the production cost of protein anti-tumor drugs can also be reduced.

GD2-specific chimeric antigen receptor effector cells for the treatment of solid tumors, which can be combined with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor. ------ The present invention relates to GD2-specific chimeric antigen receptor (GD2.CAR) effector cells for the treatment of both solid tumors, particularly extracranial GD2+ tumors (such as soft tissue sarcomas and osteosarcomas, neuroblastomas, melanomas, lung cancers, bladder cancers, and retinoblastomas) and brain tumors. Furthermore, the present invention also relates to the use of GD2.CAR gene-modified effector cells in combination with an Enhancer of Zeste Homolog 2 (EZH2) inhibitor in the treatment of solid tumors.

The present invention provides a method for constructing a mouse model of retinoblastoma, belonging to the technical field of animal models. A method for constructing a mouse model of retinoblastoma includes relieving pressure on the sclera of a mouse and injecting retinoblastoma cells into the vitreous body. First, the present invention perforates the sclera to relieve pressure, causing a part of the vitreous body to flow out, increasing the injection amount of tumor cells, avoiding the exudation of tumor cells, increasing the growth rate of tumor cells, thereby increasing the success rate of model construction, and at the same time, the eyeball remains normal. Further, the present invention uses the method of overexpressing monoclonal stable transfected cell lines of Y79 / luciferase+CopGFP genes to achieve the purpose of quantifying tumor size and dynamically detecting tumor growth under the method of fluorescence examination.

The invention discloses application of zinc pyrithione in preparation of a medicine for treating retinoblastoma, and relates to the technical field of biological medicines. On the basis of high-throughput drug screening, a small-molecule inhibitor zinc pyrithione (ZnPt) capable of efficiently inhibiting retinoblastoma (RB) cell proliferation is obtained, and the anti-tumor effect of ZnPt is verified through a series of in-vivo and in-vitro experiments. Furthermore, the invention also explores the anti-tumor action mechanism of the ZnPt, and finds that the ZnPt can play an anti-tumor role by inhibiting a glycolysis metabolic pathway. The research result of the invention provides a new strategy for developing clinical treatment of RB, and lays a foundation for precise treatment of a targeted metabolic pathway.

This invention discloses the application of BHLHE40 in the preparation of prognostic assessment kits and therapeutic drugs for retinoblastoma. Through a series of in vitro and in vivo experiments, this invention demonstrates that knocking down BHLHE40 expression significantly inhibits the proliferation of retinoblastoma cells, exhibiting a significant tumor-suppressive effect. Therefore, it is proposed that BHLHE40 inhibitors can be used in the preparation of therapeutic drugs for retinoblastoma, providing a new, effective, and safe treatment option for RB patients. Furthermore, BHLHE40 can serve as a drug target to guide subsequent drug development. In addition, this invention also utilizes clinical tumor tissue samples to demonstrate that high BHLHE40 expression is significantly positively correlated with high-risk pathological features such as optic nerve invasion, scleral invasion, and choroidal invasion, suggesting that BHLHE40 can serve as an effective biomarker for predicting high-risk pathological features, assisting physicians in treatment decisions.

The invention discloses application of a miR-3691 inhibitor in preparation of a medicine for treating retinoblastoma, and belongs to the technical field of biological medicines. The miR-3691 inhibitor is used for preparing the medicine for treating retinoblastoma, the miR-3691 inhibitor is chemically modified antisense oligonucleotide, the sequence of the miR-3691 inhibitor is shown as SEQ ID NO: 1, the miR-3691 inhibitor is realized by inhibiting proliferation and tumorigenesis of retinoblastoma cells, and the medicine takes the miR-3691 inhibitor as an active ingredient and takes the miR-3691 inhibitor as an active ingredient. The pharmaceutical composition is selected from at least one preparation form of tablets, powder, injection, capsules, suspensions, paste, gel, coating agents, medicine film agents, sustained release agents or microspheres. The miR-3691 inhibitor is proved to be capable of remarkably inhibiting the proliferation and tumorigenesis capability of retinoblastoma cells, a new clinical treatment medicine is provided for retinoblastoma, and the treatment effectiveness is improved.

The invention pertains to a binary heterojunction photosensitizer composed of graphitic carbon nitride (gCN) and black phosphorus (BP) for use in photodynamic therapy (PDT) to treat retinoblastoma. The gCN / BP binary heterojunction nanosheets enhance light absorption and charge carrier separation, activated by near-infrared (NIR) light to generate reactive oxygen species (ROS), inducing apoptosis in cancer cells. The photosensitizer accumulates selectively in tumor tissues, minimizing damage to healthy cells, and addresses BP's stability in biological environments, offering a durable, non-invasive treatment for retinoblastoma.

The application provides a preparation method and application of an anti-L1CAM antibody drug conjugate, the anti-L1CAM antibody drug conjugate comprising an anti-L1CAM single-chain antibody, a DNA / RNA hybrid chain molecule and a cytotoxin DM1; the anti-L1CAM single-chain antibody is covalently connected to one end of the DNA / RNA hybrid chain molecule; the cytotoxin DM1 is covalently connected to the other end of the DNA / RNA hybrid chain molecule; and the DNA / RNA hybrid chain molecule comprises an RNase H sensitive segment. The technical scheme of the application specifically couples the anti-L1CAM single-chain antibody and the DM1 through the DNA / RNA hybrid chain, so that the obtained antibody drug conjugate integrates targeting, intelligent release and high-efficiency killing, has the effect of inhibiting retinoblastoma proliferation, and can effectively inhibit retinoblastoma proliferation and metastasis.

The present invention provides a spherical nucleic acid nanoparticle targeting GD2 and its preparation method and application. The preparation method comprises: using siRNA nucleic acid chain, nucleic acid aptamer nucleic acid chain and small molecule inhibitor NVP-CGM097 to self-assemble to obtain spherical nucleic acid nanoparticle S-AGsM7; wherein the sequences of the sense chain and antisense chain of the siRNA nucleic acid chain are shown in SEQ ID NO.1 and SEQ ID NO.2, respectively, and the sequence of the nucleic acid aptamer nucleic acid chain is shown in SEQ ID NO.3. The spherical nucleic acid nanoparticles using the technical solution of the present invention can accurately target retinoblastoma cell lines Y79 and WERI-RB1, deliver siRNA-MDM2 and small molecule inhibitor NVP-CGM097 into cells, block the interaction between MDM2 and p53, inhibit the degradation of p53, and thus inhibit RB proliferation.

The present invention belongs to the field of biomedical technologies, and discloses the biomarker CDK12 for retinoblastoma and its applications. Specifically, it discloses the application of CDK12 as a biomarker in the development of products for diagnosing and / or preventing and / or treating retinoblastoma. The present invention for the first time discloses that CDK12 can be used as a biomarker for the diagnosis, treatment, and prognosis evaluation of RB, as well as a metastasis biomarker of RB (a biomarker for promoting the metastatic malignant phenotype of retinoblastoma), and as a drug development target for RB.

The application provides a medical image processing method and system, which comprises the following steps: inputting a to-be-processed fundus image into a local feature extraction backbone network and a global feature extraction backbone network in a medical image recognition model; inputting local image features and global image features extracted by the backbone network into a feature mapping layer in the medical image recognition model; inputting first mapping features and second mapping features mapped by the feature mapping layer into a feature decoupling layer in the medical image recognition model; inputting first specificity features, second specificity features and shared features decoupled by the feature decoupling layer into a classification layer in the medical image recognition model; inputting recognition probability distribution vectors, corresponding prediction entropies and prediction confidences output by each classifier in the classification layer into a weighted aggregation layer in the medical image recognition model; and adaptively aggregating to obtain retinoblastoma recognition results corresponding to the to-be-processed fundus image, thereby effectively improving the accuracy and reliability of the retinoblastoma recognition results.

An epigenetic silencer factor (ESP), or polynucleotide encoding therefor, for use in the treatment of cancer, wherein the ESF comprises a transcription factor DNA-binding domain operably linked to at least one epigenetic effector domain, wherein the transcription factor is an oncogenic transcription factor or a cancer-associated transcription factor, wherein the cancer is selected from the group consisting of: glioma, gliobastoma, medulloblastoma, astrocytoma, neuroblastomas, ependymoma, meningioma, retinoblastoma, rhabdomyosarcoma, lung cancer, prostate cancer, breast cancer, liver cancer, pancreatic cancer (e.g. human pancreatic ductal adenocarcinoma), bladder cancer, oropharyngeal cancer, kidney cancer, colon cancer (e.g. colon adenocarcinoma), colon-rectal cancer (CRC), or a metastasis of any of the foregoing.